Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2025 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

"Our cells naturally become more mesenchymal over time, so PRP’s ability to potentially reverse this trend is of tremendous scientific interest"
December 02, 2025 09:00 ET | Source: BetaGlue Therapeutics SpA

BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining from the Italian Ministry of Health Approval to conduct its clinical study in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

MILAN, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for...
December 02, 2025 04:00 ET | Source: Tacalyx GmbH

Tacalyx Appoints Jean Engela as Chief Executive Officer to Spearhead Next Phase of Growth

Berlin, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tacalyx, a privately held biotech company focused on developing novel TACA (Tumour Associated Carbohydrate Antigens) cancer therapies, announces...
November 17, 2025 01:00 ET | Source: AKAMPION

Captain T Cell Closes Financing Round to Advance its Proprietary, Next-Generation TCR-T Pipeline Into the Clinic

Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet medical needSpringboard Health Angels, Pluton Asset Holding AG, Sintra Limited,...
November 07, 2025 07:00 ET | Source: GenVivo, Inc.

GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Systemic Cancer Immunotherapy, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no Dose Limiting Toxicity or treatment-related...
October 18, 2025 03:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607...
September 17, 2025 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

A certificate of grant for Propanc’s “proenzyme composition” patent was received from the US Patent & Trademark Office.
August 25, 2025 07:30 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Shareholder Update

Propanc is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study
July 31, 2025 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines

TORONTO and HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...
June 18, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Announces Strengthening of Leadership: Alessandra Cesano Joins Board of Directors, Florian D. Vogl Appointed Chief Medical Officer

Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of...